SEARCH · PubMed Health
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
PURPOSE: To evaluate the outcome of women with hypogonadotropic hypogonadism undergoing in-vitro fertilization (IVF). METHODS: We retrospectively assessed outcomes in 58 women with hypogonadotropic hypogonadism (HH) and, as matched controls, in 116 women with tubal factor (TF) infertility who underwent assisted reproduction treatment (ART). For ovulation induction, human menopausal gonadotropin (hMG) was used in HH patients and a combination of hMG and gonadotropin releasing hormone (GnRH) agonist was used in TF patients. Conception and implantation rates, as well as duration of stimulation and number of oocytes retrieved, were the main outcome measures. RESULTS: Of the 58 HH patients, 53 (91.3%) responded adequately to ovulation induction and underwent ET. A larger amount of gonadotropins and a longer duration of ovarian stimulation were needed in HH patients than in TF patients. The mean number of retrieved oocytes and implantation rates did not differ between the groups. In addition, there were no differences between the HH and TF groups in pregnancy (53.8 vs. 48.6%) and multiple pregnancy (63.4 vs. 48.4%) rates. In the HH group, the miscarriage rate was 3.4%, and none of these patients developed severe OHSS. CONCLUSION: IVF in HH patients, in which there was a background of previous failed ovulation induction, was as successful as in women with TF infertility.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
UNLABELLED: Levonorgestrel is one of the contraceptives used by women during lactation. Previous studies have shown that the administration of levonorgestrel to lactating female rats has affected the offspring, causing puberty delay in males and alterations on uterus and oviduct weight. PURPOSE: To study the reproductive capacity of F1 females from rats treated with levonorgestrel. METHODS: Female Wistar rats were treated with levonorgestrel (0.030 mg/1 ml of distilled water) from day 7 to day 13 after birth (day 1 = birth). On day 90 F1 females were mated with fertile males and insemination was confirmed by the presence of spermatozoa in the vaginal smear (first day of pregnancy). Inseminated females were distributed in three groups of 20 animals each (10 F1 control and 10 F1 treated). The animals were killed on days 2, 4 and 5 after insemination by ether overdose inhalation and the ovaries, oviducts and uterine cornua were removed. The ovaries were weighed and the corpora lutea counted. Oviducts and corpora lutea were washed with saline solution and the pre-embryos were counted and examined in all segments. RESULTS: The ovaries weight, the number of corpora lutea, the number and development phase of the pre-embryos were similar in both groups. CONCLUSION: In the experimental model used, F1 females whose mothers were treated with levonorgestrel during lactation, did not show any alteration in their reproductive capacity.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Factors influencing the age-related decline in production parameters of broiler breeder hens are poorly understood. Elevated blood glucose concentrations measured in broiler breeder hens may contribute to this decline. The nonenzymatic attachment of glucose to proteins generates glycoxidation crosslinks in tissue proteins, which can ultimately impair their function. One such glycoxidation crosslink, pentosidine, has been used as a biomarker for aging studies because of its accumulation on the structural protein collagen. The objectives of these studies were to determine whether pentosidine accumulates with age in hens and whether the crosslinking inhibitor, aminoguanidine (AG), could retard this accumulation. An additional objective was to determine whether AG had any effect on production performance. In the first study, broiler breeder hens (n = 318) were randomly assigned to two groups: control and supplemented (400 ppm AG). Pentosidine was measured in the skin of the birds at 20 and 67 wk of age. Egg production was measured daily. In a second study, broiler breeder hens (n = 60) were reared as previously described. Pentosidine was measured in the skin of the birds at 20 and 68 wk of age. Results showed that pentosidine was present in the skin of the hens, and that concentrations increased with age (P < 0.001). Although pentosidine was reduced (P < 0.001) in AG-supplemented birds, production performance was not affected. In conclusion, AG retarded the rate of accumulation of pentosidine during lay in broiler breeder hens, but the reduction in pentosidine did not significantly affect production performance.